A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
|ClinicalTrials.gov Identifier: NCT00144144|
Recruitment Status : Unknown
Verified July 2006 by Advanced-J.
Recruitment status was: Active, not recruiting
First Posted : September 5, 2005
Last Update Posted : July 14, 2006
|Condition or disease||Intervention/treatment||Phase|
|Hypertension Diabetes Mellitus, Type 2||Drug: Angiotensin II receptor antagonists, Calcium channel blocker||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists|
|Study Start Date :||September 2004|
|Estimated Study Completion Date :||September 2008|
- Changes in blood pressure level at home after getting up.
- The rate of the blood pressure levels at home after getting up, which effected the target levels (systolic blood pressure < 125 mm Hg, diastolic blood pressure < 80 mm Hg).
- Adverse events, adverse drug reactions
- Clinical laboratory data
- Changes in blood pressure levels measured on an outpatient basis.
- The rate of the blood pressure levels measured on an outpatient basis, which effected the standard levels (systolic blood pressure level <130 mm Hg, diastolic blood pressure level < 80 mm Hg).
- Changes in blood pressure levels measured at home before going to bed· Changes in IMT of the cervical artery
- Changes in PWV· Changes in echocardiographic findings
- Changes in urinary albumin level
- Changes in BNP· Changes in hs-CRP· Medical cost-effectiveness
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00144144
|Dept. of Clinical Immunology, Clinical Bioinformatics Research Unit, Graduate School of Medicine, the University of Tokyo|
|Hongo, Bunkyo-ku, Tokyo, Japan, 113-8655|
|Principal Investigator:||Ryuzo Kawamori, M.D.||Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism|